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Newly diagnosed invasive breast cancers should be evaluated for Human Epidermal Growth Factor Receptor 2 (HER2) status by immunohistochemistry (IHC) and/or in situ hybridisation (ISH) to determine eligibility for trastuzumab or other HER2-targeted therapies. Previous reports of high discordance rates between IHC and ISH have raised concerns over the accuracy of HER2 testing, especially when IHC is conducted locally. This study aimed to determine the rate of false-negative IHC results at three pathology centres (one central, two local) in Greece by central retesting of 240 prospectively collected invasive breast cancers scored as IHC 0/1+ at initial testing. All samples were from female patients (median age 58.0 years). Initial IHC tests utilised either the CB11 (159/239; 66.5%) or 4B5 (80/239; 33.5%) antibodies and were scored as 0 in 105/240 cases (43.8%) and 1+ in 135/240 cases (56.3%). All samples were centrally retested by automated silver in situ hybridisation (SISH). Of 237 samples with SISH staining suitable for assessment, 223 (94.1%; 95% confidence interval 90.3-96.5%) were classed as SISH-negative (HER2:chromosome enumeration probe 17 (CEP17) <1.8). Eight tested SISH-positive (HER2:CEP17 >2.2), providing a false-negative rate of 3.4%. A further four samples (1.7%) exhibited equivocal amplification status (HER2:CEP17 1.8-2.2) and two (0.8%) showed polysomy of chromosome 17. The proportion of SISHnegative results did not significantly differ between the IHC 0 and 1+ subgroups (95.2% vs. 93.2%; p=0.505) . In conclusion, the low observed rate of false-negative IHC results in this study supports the use of IHC for initial HER2 status assessment in local or central laboratories in Greece.
early and metastatic disease [2] [3] [4] [5] [6] [7] and is established as the standard of care [8] [9] [10] . Because HER2 status predicts trastuzumab response [2, 11] , accurate HER2 testing is essential to determine which patients are most likely to benefit from this treatment. HER2 assessment is also used to determine eligibility for three other anti-HER2 therapies, pertuzumab (PERJETA ® , F. HoffmannLa Roche; Genentech Inc., South San Francisco, CA, USA) [12] , T-DM1 (Kadcyla ® , F. Hoffmann-La Roche; Genentech Inc.) [13] and lapatinib [14] , and may additionally predict response or resistance to certain chemotherapeutic and hormonal therapies [15] .
Two diagnostic techniques are routinely used for determination of HER2 status: immunohistochemistry (IHC) and in situ hybridisation (ISH) [16] . IHC is a semiquantitative technique in which a HER2-specific antibody is used to evaluate the level of HER2 protein expression in fresh, frozen or formalin-fixed, paraffin-embedded tissue sections. Although relatively fast and inexpensive to perform, the reliability of IHC is susceptible both to inter-observer variability in interpretation and to a variety of pre-analytic and analytic factors that can influence antibody staining [1, 16] . In contrast, ISH is a quantitative assay that uses a labelled DNA probe to determine HER2 copy number, often alongside a second probe for the chromosome 17 centromere (chromosome enumeration probe 17 (CEP17)) to control for aneusomy of chromosome 17 [16] . The first available HER2 ISH assays were fluorescence ISH (FISH) tests, which, although considered more reproducible than IHC, require a specialised fluorescence microscope for analysis and are subject to limited stability of fluorophore signals [16] . More recently, bright-field ISH techniques, including chromogenic ISH and silver-enhanced ISH (SISH), have been developed, which are analysed using conventional bright-field microscopy and permit evaluation of histological features alongside HER2 amplification status [16] . SISH has been developed as a fully automated assay that shows low inter-observer variability and high concordance with validated FISH assays [17, 18] .
Both IHC and ISH are recommended for initial HER2 testing [1], but IHC is more widely used in clinical practice [19] , with ISH testing typically reserved for reflex testing of samples with an equivocal IHC (2+) score. However, previous studies have identified high rates of discordance between IHC and ISH, including both falsenegative (i.e., IHC-negative/ISH-positive) and falsepositive (i.e., IHC-positive/ISH-negative) IHC results [20] , especially when comparing local IHC with central ISH assessments [21] . To improve the accuracy of HER2 testing in breast cancer, the American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) issued guidelines in 2007 for standardisation of HER2 assessment, which recommended that HER2 tests in individual laboratories should show at least 95% concordance with a validated assay [1] . The impact of this guidance on the accuracy of HER2 testing is not fully established, but recent evidence suggests a modest decline in the incidence of false-negative results at one US centre following the publication of the ASCO/CAP document [22] .
To assess the accuracy of IHC testing in current pathology practice, an international study is evaluating the rate of false-negative IHC results by central SISH retesting of approximately 1800 prospectively collected breast cancers with negative (0 or 1+) IHC scores. Here, we report results from the three Greek laboratories participating in this study, which provide an estimate of the incidence of false-negative IHC scores in routine breast cancer testing in Greece.
Materials and methods
Patient samples
Three pathology centres (two local and one central laboratory) in Greece each contributed 80 resected, prospectively collected invasive breast cancer specimens for central retesting (n=240). For inclusion, samples were required to have been scored as IHC 0 or 1+ at initial testing. IHC was performed using either the CB11 (Leica Biosystems Ltd, Newcastle Upon Tyne, UK) or PATHWAY 4B5 (Ventana Medical Systems Inc., Tucson, AZ) primary antibodies according to the manufacturers' instructions. Staining for HER2 scoring was interpreted according to ASCO/CAP 2007 [1] criteria as follows: Regions containing all cells with no staining or if cell membrane staining is observed in <10% of the tumour cells received a score of 0 ('negative'). Regions containing more than 10% of cells with a faint perceptible membrane staining received a score of 1+ ('negative'). Regions containing more than 10% of cells with weakto-moderate complete membrane staining received a score of 2+ ('weakly positive'). Regions containing more than 30% of cells with a strong complete membrane staining received a score of 3+ ('positive').
Central SISH retesting
Recently cut tissue sections from the same blocks used for initial IHC analysis were provided to the central laboratory (Pathology Department, Hygeia Hospital, Athens) for SISH retesting. SISH was conducted using the INFORM HER2 Dual ISH DNA Probe Cocktail (Ventana Medical Systems Inc.), which contains a dinitrophenol (DNP)-labelled HER2 probe and a digoxigenin (DIG)-Central retesting of breast cancer with HER2 immunohistochemistry score of 0 or 1+ using silver-enhanced in situ hybridisation: a multicentre, prospective study in Greece labelled CEP17. Hybridised probes were detected using the ultraVIEW Silver ISH DNP (SISH) and ultraVIEW Red ISH DIG Detection Kits (Ventana Medical Systems Inc.), which visualise HER2 and CEP17 as black and red signals, respectively. The staining procedure was fully automated using the BenchMark ULTRA machine (Ventana Medical Systems Inc.). SISH was performed in accordance with the manufacturer's protocols by central laboratory personnel, who could access specialised support from the manufacturer if required. Prior to initiation of the study, the quality of SISH tests in the central laboratory was confirmed by the manufacturer.
For each sample, 60 nuclei were evaluated and HER2 status assigned using ASCO/CAP criteria according to the mean HER2:CEP17 ratio as positive (ratio >2.2), negative (ratio <1.8) or equivocal (ratio 1.8-2.2) [1] . For cases with a ratio of 1.8-2.2, an additional 20 nuclei were counted to determine the final status. In addition, the presence of polysomy of chromosome 17 was recorded where the mean number of CEP17 signals was ≥3 signals/cell.
Statistical analyses
Descriptive statistics were used to summarise patient characteristics and assay results. For continuous variables, these included measures of central tendency (median, mean) and dispersion (interquartile range (IQR), standard deviation). Categorical variables were summarised as frequencies and percentages. The distribution of HER2:CEP17 ratios was summarised as a histogram and kernel density estimation plot. The main study endpoint was the proportion of samples with initial IHC 0/1+ (i.e., negative) scores that were also classified as SISH-negative on central retesting. The two-sided 95% confidence interval (CI) for this endpoint was derived using the Agresti-Coull method [23] . The proportions of SISH-negative results were compared between the IHC 0 and IHC 1+ subgroups using Pearson's chi-square test of independence. All statistical analyses were conducted using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Results
Patient population
A total of 240 cases of invasive breast cancer with IHC score of 0 or 1+ were included in the study. Clinical characteristics of the study population are summarised in Table 1 . All patients were female and the median age was 58.0 years (IQR 48.0-68.0 years). Pathological material was mostly obtained from partial (57.1%) or radical/modified radical mastectomy (39.2%), but a minority of samples were obtained via biopsy or other procedures (3.3%).
Initial assessment of HER2 status using IHC
Results of initial IHC testing of these 240 samples are summarised in Table 2 . The median duration between surgery and date of IHC examination was 6.0 days (IQR 2.0-11.0 days). For the preparation of slides, the CB11 Novocastra antibody was used in 159 (66.5%) of the 
Central reassessment of HER2 status using SISH
The median time between surgery and central HER2 reassessment by SISH was 4.6 months (IQR 2.5-8.0 months). Characteristics of the SISH assay are summarised in Table 3 . Most samples analysed (n=221, 92.1%) showed homogeneous SISH staining, with a minority showing heterogeneous (3.8%) or focal (2.9%) staining patterns. Three samples showed no staining and were deemed by the investigator as unsuitable for HER2 status assessment.
Results of the SISH HER2 reassessment are summarised in Table 4 and Fig. 1 . Of the 237 evaluable samples, 225 had HER2:CEP17 ratio <1.8; therefore, the proportion of IHC 0/1+ cases that were classed as HER2-negative when re-examined using SISH was estimated at 94.9% (95% CI 90.3-96.5%) included the two (0.8%) samples that showed polysomy of chromosome 17. Eight of the 237 samples tested positive by SISH (HER2:CEP17 >2.2), providing a falsenegative rate of 3.4%. Four cases (1.7%) exhibited equivocal HER2 amplification status (HER2:CEP17 ratio 1.8-2.2).
Comparing tumours with IHC score of 0 with those with IHC score of 1+, the distribution of samples between the SISH-positive, SISH-equivocal and SISHnegative categories appeared similar. Among the 105 IHC 0 samples, 100 (95.2%) were classed as negative, one was equivocal (1.0%) and four (3.8%) were positive by SISH. Of the 132 IHC 1+ samples, 123 (93.2%) were negative, three (2.3%) were equivocal and four (3.0%) tested SISH-positive. There was no significant difference between the proportion of cases scored as SISH-negative in the IHC 0 subgroup compared with the IHC 1+ subgroup (95.2% vs. 93.2%; p=0.505). Central retesting of breast cancer with HER2 immunohistochemistry score of 0 or 1+ using silver-enhanced in situ hybridisation: a multicentre, prospective study in Greece
Discussion
This study was conducted to determine the rate of falsenegative IHC results among prospectively collected invasive breast cancers by central SISH retesting of samples scored as IHC 0/1+ at initial assessment in three Greek pathology laboratories. Its main finding is that only eight of the 237 evaluable samples (3.4%) yielded a positive SISH result when retested at the central facility. HER2 amplification among these eight tumours was mostly at the low level, with all but one having HER2:CEP17 ratios between 2.3 and 2.7. The low rate of false-negative IHC results across the three centres supports an approach of first-line IHC testing with reflex ISH testing being reserved for IHC 2+ cases, which is one of the strategies recommended by ASCO/ CAP [1] . The ongoing international study of 1800 IHC 0/1+ cases, of which this analysis is a part, will provide further information on the 'real-world' incidence of falsenegative IHC results in a larger set of samples from several different countries.
Although generally in agreement, the results of IHC and ISH assays are not fully concordant, even when performed in the same laboratory [24, 25] and both false-negative and false-positive IHC results are reported to affect substantial minorities of samples [20] . Discordance may be most pronounced between local IHC and central ISH evaluations [21, 26] . Indeed, prospective patient screening data from adjuvant trastuzumab trials highlighted a high rate of discordance between local and central assessments even when comparing results of the same technique [27, 28] .
An early estimate of the rate of false-negative IHC results at local laboratories was provided by Reddy and coworkers who centrally retested all breast cancers that had been locally evaluated for HER2 status during screening for a community-based study of trastuzumab between 2001 and 2004 [29] . Of the 383 samples initially scored as IHC 0/1+, 16 (4.2%) were reassessed as FISH-positive at the central laboratory. Similarly, in a previous Greek study including 88 samples evaluated as IHC 0/1+ at initial testing in central or local laboratories between 2001 and 2005, eight (9.1%) were centrally reassessed as HER2-amplified by FISH [21] . The 3.4% incidence of false-negatives reported in the present study compares favourably with this previous estimate and is consistent with an improvement in the accuracy of IHC testing in Greek pathology practice over time, although there are differences in methodology and participating centres between these two studies. A USbased study has also provided evidence of a modest fall in the incidence of false-negative IHC results since the publication of the ASCO/CAP guidelines [22] .
The false-negative rate in the present study is comparable with recent reports from other countries [30] [31] [32] [33] . For example, in a study of IHC 0/1+ samples from five centres in Austria, 25 of 570 (4.4%) were centrally scored as ISH-positive when assessed using the ASCO/CAP HER2:CEP17 cut-off (>2.2) [31] . Using the FDA definition of ISH-positivity (HER2:CEP17 >2.0), Larsimont et al demonstrated a 3.1% false-negative rate among 456 IHC 0/1+ samples from 34 centres in Belgium [30] . Similarly, a false-negative rate of 2.9% has been reported in a single-centre retrospective study conducted in Korea [33] . The lower incidences of false-negative results recently reported in studies conducted in the US [22] and Canada [32] (1.9% and 1.0%, respectively) may reflect the centralisation of IHC testing in both of these studies.
False-negative IHC results are commonly attributed to the various pre-analytic and analytic factors that can influence the extent of immunostaining [1] . For example, formalin fixation and paraffin embedding are known to reduce the immunogenicity of the sample and so may explain a proportion of false-negative cases [34, 35] . Although antigen retrieval processes such as heat treatment can partially reverse these effects, this introduces a further potential source of variability into the assay [24] . For these reasons the ASCO/CAP guidelines emphasise the need for standardisation of sample preparation [1] . Interestingly, 17/24 (71%) of 'false-negative' samples in the Austrian retesting study acquired a 2+ or 3+ IHC score when IHC was repeated at the central facility [31] . In the present study, we did not attempt to verify the initial IHC test result, but the false-negative cases appeared to be evenly distributed between the three participating centres, one of which was the central laboratory. Although differences in antibody characteristics used might also influence the IHC staining, there was no indication that the rate of false-negative IHC results differed between the two antibodies utilised in the present study, which is consistent with previous data [36] . A further potential source of discrepant IHC/ISH results is focal loss of the chromosome 17 centromere, which can elevate the HER2:CEP17 ratio in the absence of HER2 gene amplification [37] . Although a previous study found falsenegative cases to be enriched for tumours with reduced CEP17 count [38] , all SISH-positive cases in the present study had mean CEP17 count of ≥2.0/cell, suggesting that this was not a cause of discordance.
The clinical significance of false-negative IHC results is currently unclear. Whereas patients with falsepositive results (i.e., those with a positive local HER2 assessment that was not confirmed on central testing) have been included in clinical trials of trastuzumab [39, Wolff AC, Hammond ME, Schwartz JN, Hagerty KL,
40], there are no efficacy data available for patients with known false-negative IHC results, who would have been excluded from trial entry based on their 'negative' IHC score. Nevertheless, these tumours are clearly ISHpositive and so the potential for this patient subgroup to benefit from trastuzumab is an important issue for future study, as is the potential prognostic relevance of IHC-negative/ISH-positive status. Interestingly, a recent study demonstrated that an equivocal (2+) IHC score, in the absence of HER2 amplification, was associated with poorer disease-free survival compared with patients with negative (0/1+) IHC scores [41] . Future studies should also explore the potential association of falsenegative IHC status with other histopathologic features such as hormone receptor status, Ki-67 or histologic grade, which could facilitate the identification of tumours most likely to benefit from confirmatory ISH even if the IHC test is negative.
A major strength of this study is its evaluation of a large number of prospectively collected IHC 0/1+ samples using validated automated SISH testing at a high-throughput central facility. One limitation is the lack of blinding of investigators at the central site to the initial IHC result, which could have biased the assessment. Furthermore, this study did not examine concordance between IHC and ISH testing for IHC 2+ or 3+ cases.
In conclusion, the present study demonstrates high concordance between initial IHC testing and central SISH retesting among IHC 0/1+ tumours in Greek pathology practice, with a low rate of false-negative IHC results, thereby supporting an approach of initial IHC testing with reflex ISH for equivocal cases. Further improvement in the accuracy of HER2 assessment may be provided by a new protein-guided ISH assay that permits simultaneous evaluation of HER2 expression and HER2 copy number and correctly identifies falsenegative cases using a single, automated assay [42] .
